(Q37417693)

20 August 2017

1 reference

title

Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis (English)

1 reference

20 August 2017

1 reference

1 reference

1 reference

Shaista Malik

1

1 reference

20 August 2017

Nathan D Wong

series ordinal

2

1 reference

20 August 2017

publication date

1 March 2009

1 reference

Expert Review of Cardiovascular Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

7

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

273-280

1 reference

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

High prevalence of metabolic syndrome in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

High prevalence of metabolic syndrome in Hong Kong Chinese--comparison of three diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Intima media thickness as a surrogate marker for generalised atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome and the progression of carotid intima-media thickness in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome and echocardiographic left ventricular mass in blacks - the atherosclerosis risk in communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

The impact of metabolic syndrome on left ventricular function: evaluated by using the index of myocardial performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Prediction of coronary events with electron beam computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

The metabolic syndrome, diabetes, and subclinicalatherosclerosis assessed by coronary calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome and diabetes are associated with an increased likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

High-normal fasting blood glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Mortality over a period of 10 years in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Cardiovascular disease risk stratification with stress single-photon emission computed tomography technetium-99m tetrofosmin imaging in patients with the metabolic syndrome and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Prevalence and Prognostic Impact of Subclinical Cardiovascular Disease in Individuals With the Metabolic Syndrome and Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.273

21 January 2018

Identifiers

DOI

10.1586/14779072.7.3.273

1 reference

20 August 2017

1 reference